U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07938632) titled 'TL-925 for the Treatment of Allergic Conjunctivitis' on Nov. 06.
Brief Summary: In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 100 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.
The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Allergic Conjunctivitis of Both Eyes
Intervention:
DRUG: TL-925
TL-925 is an eye...